The reduced anticoagulant effect of fondaparinux at low antithrombin levels

Anesthesia and Analgesia

Volumn 109, Issue 3, 2009, Pages 712-716

  Dempfle, Carl Erik ^a   Eichner, Julia ^a   Suvajac, Nenad ^a   Ahmad Nejad, Parviz ^a   Neumaier, Michael ^a   Borggrefe, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; FONDAPARINUX; ANTICOAGULANT AGENT; HEPARIN; POLYSACCHARIDE;

ANTICOAGULATION; ANTITHROMBIN DEFICIENCY; ARTICLE; BINDING SITE; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; HUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD CLOTTING; CHEMISTRY; DRUG EFFECT; METABOLISM; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPARIN; HUMANS; POLYSACCHARIDES; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 70149114864     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e3181ae94b0     Document Type: Article

References (17)

1. Olson ST, Chuang YJ. Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc Med 2002;12:331-8 (Pubitemid 36092123)
2. Mayr AJ, Dunser M, Jochberger S, Fries D, Klingler A, Joannidis M, Hasibeder W, Schobersberger W. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res 2002;105:201-4 (Pubitemid 34260941)
3. Jochberger S, Mayr V, Luckner G, Fries DR, Mayr AJ, Friesenecker BE, Lorenz I, Hasibeder WR, Ulmer H, Schobersberger W, Dunser MW. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study. Crit Care 2005;9:R541-8
4. Young E, Podor TJ, Venner T, Hirsh J. Induction of the acutephase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vasc Biol 1997;17:1568-74 (Pubitemid 27387779)
5. Manson L, Weitz JI, Podor TJ, Hirsh J, Young E. The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. J Lab Clin Med 1997;130:649-55 (Pubitemid 28029234)
6. Avidan MS, Levy JH, Scholz J, Delphin E, Rosseel PM, Howie MB, Gratz I, Bush CR, Skubas N, Aldea GS, Licina M, Bonfiglio LJ, Kajdasz DK, Ott E, Despotis GJ. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparinresistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005; 102:276-84 (Pubitemid 40189074)
7. Avidan MS, Levy JH, van Aken H, Feneck RO, Latimer RD, Ott E, Martin E, Birnbaum DE, Bonfiglio LJ, Kajdasz DK, Despotis GJ. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005;130:107-13 (Pubitemid 40941676)
8. Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert JM, van Boeckel CA, Meuleman DG. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents-the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002;20:37-52 (Pubitemid 34657226)
9. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983;116:492-9 (Pubitemid 14242772)
10. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003;109:1-11 (Pubitemid 36385042)
11. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-10
12. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345:1298-304
13. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78 (Pubitemid 33010239)
14. Yin ET, Wessler S, Butler JV. Plasma heparin: a unique, practical, submicrogram-sensitive assay. J Lab Clin Med 1973; 81:298-310
15. Levy JH, Montes F, Szlam F, Hillyer CD. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000;90:1076-9 (Pubitemid 30253452)
16. Hoffmann JN, Wiedermann CJ, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Warren BL, Opal SM. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006;95:850-6
17. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006;4:90-7